Posted by Michael Wonder on 16 Aug 2018
US insurers can peg access to ICER value reviews
16 August 2018 - Latest step in US pricing evolution.
US pharmacy benefit manager CVS Caremark is to start using cost-effectiveness analyses by ICER to decide if drugs should be excluded from its plans.
In a just-published white paper entitled Current and new approaches to making drugs more affordable, CVS says its clients will be able to exclude any drug launched at a cost of more than $100,000 per quality-adjusted life year based on ICER’s calculations unless they have breakthrough status from the FDA.
